Migraine headache relief supplement natural medicine to help prevent migraine headaches

Migraine Headache Relief
Used in Herbal Medicine to help prevent migraine headaches

What is a migraine headache?

A migraine headache is a form of vascular headache. Migraine headache is caused by vasodilatation (enlargement of blood vessels) that causes the release of chemicals from nerve fibers that coil around the large arteries of the brain. Enlargement of these blood vessels stretches the nerves that coil around them and causes the nerves to release chemicals. The chemicals cause inflammation, pain, and further enlargement of the artery. The increasing enlargement of the arteries magnifies the pain.

Migraine attacks commonly activate the sympathetic nervous system in the body. The sympathetic nervous system is often thought of as the part of the nervous system that controls primitive responses to stress and pain, the so-called "fight or flight" response, and this activation causes many of the symptoms associated with migraine attacks; for example, the increased sympathetic nervous activity in the intestine causes nausea, vomiting, and diarrhea.

• Migraine prevention: Use for a minimum of 4-6 weeks to see beneficial effects

• Migraine prophylaxis: Use for a minimum of 4-6 weeks to see beneficial effects

Click Here ->

References reviewed

•Abebe W. 2002. Herbal medication: potential for adverse interactions with analgesic drugs. Journal of Clinical Pharmacy and Therapeutics 27(6):391-401.

•Anderson D, Jenkinson PC, Dewdney RS, Blowers SD, Johnson ES, Kadam NP. 1988. Chromosomal aberrations and sister chromatid exchanges in lymphocytes and urine mutagenicity of migraine patients: a comparison of chronic feverfew users and matched non-users. Human Toxicology 7(2):145-152.

•Awang DVC, Dawson BA, Kindack DG. 1991. Parthenolide content of feverfew (Tanacetum parthenium) assessed by HPLC and 1H-NMR spectroscopy. Journal of Natural Products 54(6):1516-1521.

•Bedard M. 2002. Feverfew and migraine prophylaxis. Canadian Pharmaceutical Journal/La Revue Pharmaceutique Canadienne 4:24-25.

•Berry MI. 1984. Feverfew faces the future. Pharmaceutical Journal 232:611-614.

•BHP 1996: British Herbal Pharmacopoeia. Bournemouth (UK): British Herbal Medical Association; 1996.

•Blumenthal M, Hall T, Goldberg A, Kunz T, Kinda K, editors. 2003. The ABC Clinical Guide to Herbs. Austin (TX): American Botanical Council

•Brinker F. 2008. Online Updates and Additions to Herb Contraindications and Drug Interactions, 3rd edition. Sandy (OR): Eclectic Medical Publications. [Accessed 2008-03-07]. Available from: http://www.eclecticherb.com/emp/updatesHCDI.html

•Brown AM, Edwards CM, Davey MR, Power JB, Lowe KC. 1997. Pharmacological activity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.): assessment by inhibition of human polymorphonuclear leukocyte chemiluminescence in-vitro. Journal of Pharmacy and Pharmacology 49(5):558-561.

•Brown D, Gaby A, Reichert R. 1997. Clinical applications of natural medicine: migraine. American Journal of Natural Medicine 4(9):18-20.

•Colodny L, Bryan N, Luong S, Rooney J. 2003. Magnesium, feverfew, and riboflavin: therapeutic use in migraine prevention. Journal of American Nutraceutical Association 6(4):35-48.

•De Weerdt CJ, Bootsma HPR, Hendricks H. 1996. Herbal medicines in migraine prevention: Randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine 3(3):225-230.

•Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH. 2005. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention -- a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia: An International Journal of Headache 25(11):1031-1041.

•Draves AH, Walker SE. 2003. Parthenolide content of Canadian commercial feverfew preparations: label claims are misleading in most cases. Canadian Pharmaceutical Journal/La Revue Pharmaceutique Canadienne 136(10):23-30.

•Ernst E, Pittler MH. 2000. The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health Nutrition 3(4A):509-514.

•Farnsworth NR, Bingel AS, Cordell GA, Crane FA, Fong HH. 1975. Potential value of plants as sources of new antifertility agents I. Journal of Pharmaceutical Sciences 64(4):535-598.

•Gawel MJ. 1995. The use of feverfew in the prophylaxis of migraine attacks. Today's Therapeutic Trends 13(2):79-86.

•Grieve M. 1971. A Modern Herbal, Volume 1. New York (NY): Dover Publications [Reprint of 1931 Harcourt, Brace & Company publication].

•Hausen BM, Osmundsen PE. 1983. Contact allergy to parthenolide in Tanacetum parthenium (L.) Schulz-Bip. (feverfew, Asteraceae) and cross-reactions to related sesquiterpene lactone containing Compositae species. Acta Dermato-Venereologica 63(4):308-314.

•Heptinstall S, Awang DV, Dawson BA, Kindack D, Knight DW, May J. 1992. Parthenolide content and bioactivity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.). Estimation of commercial and authenticated feverfew products. Journal of Pharmacy and Pharmacology 44(5):391-395.

•Heptinstall S. 1988. Feverfew-an ancient remedy for modern times? Journal of the Royal Society of Medicine 81(7):373-374.
•Jain NK, Kulkarni SK. 1999. Antinociceptive and anti-inflammatory effects of Tanacetum parthenium L. extract in mice and rats. Journal of Ethnopharmacology 68(1-3):251-259.

•Klepser TB, Klepser ME. 1999. Unsafe and potentially safe herbal therapies. American Journal of Health-System Pharmacy 56(2):125-138.

•Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. 2001. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chemistry & Biology 8(8):759-766.

•Makheja AN, Bailey JM. 1982. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins, Leukotrienes, and Medicine 8(6):653-660.

•Meyer JE. The Herbalist. Glenwood (IL): Meyerbooks; 1993.

•Miller LG. 1998. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Archives of Internal Medicine 158(20):2200-2211.

•Mills S. The Dictionary of Modern Herbalsim. Wellingborough (UK): Thorsons Publishers Ltd; 1985.

•Nelson MH, Cobb SE, Shelton J. 2002. Variations in parthenolide content and daily dose of feverfew products. American Journal of Health-System Pharmacy 59(16):1527-1531.

•Pattrick M, Heptinstall S, Doherty M. 1989. Feverfew in rheumatoid arthritis: a double blind, placebo controlled study. Annals of the Rheumatic Diseases 48(7):547-549.

•Paulsen E, Andersen KE, Hausen BM. 1993. Compositae dermatitis in a Danish dermatology department in one year (I). Results of routine patch testing with the sesquiterpene lactone mix supplemented with aimed patch testing with extracts and sesquiterpene lactones of Compositae plants. Contact Dermatitis 29(1):6-10.

•Tilgner S. Herbal Medicine from the Heart of the Earth. Creswell (OR): Wise Acre Press; 1999.
•Williamson EM, Evans FJ, Wren RC. Potter's New Cyclopaedia of Botanical Drugs and Preparations. Saffron Walden (UK): C.W. Daniel Company Limited; 1988.
•Wren RC. 1907. Potter's Cyclopedia of Botanical Drugs and Preparations. London (GB): Potter and Clark.

Caution(s) and Warning(s) •Consult a health care practitioner if symptoms persist.
•Consult a health care practitioner if symptoms worsen.
•Consult a health care practitioner prior to use if you are breastfeeding (Boon 2000)
•Consult a health care practitioner prior to use if you are taking blood thinners

Minimum order is 12 units plus for wholesale pricing - Please contact us E-mail for further details.